AstraZeneca-Daiichi's Enhertu follow-up unable to prove overall survival benefit in phase 3

0

27.05.2024 16:40

Fiercebiotech.com

AstraZeneca-Daiichi's Enhertu follow-up unable to prove overall survival benefit in phase 3 jwaldron Mon, 05/27/2024 - 09:40

СМИ24.net — правдивые новости, непрерывно 24/7 на русском языке с ежеминутным обновлением *